Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

4.35USD
16 Feb 2018
Change (% chg)

$0.14 (+3.33%)
Prev Close
$4.21
Open
$4.16
Day's High
$4.37
Day's Low
$4.04
Volume
475,973
Avg. Vol
313,617
52-wk High
$5.44
52-wk Low
$3.20

Chart for

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $409.77
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders

* AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text (http://bit.ly/2n84why) Further company coverage:

24 Jan 2018

BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1

* AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034)

22 Jan 2018

BRIEF-Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners

* AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS

08 Jan 2018

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

GlaxoSmithKline adult shingles vaccine wins U.S. approval

The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.

20 Oct 2017

GlaxoSmithKline adult shingles vaccine wins U.S. approval

Oct 20 The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.

20 Oct 2017

BRIEF-Agenus files for mixed shelf of up to $250 million

* Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​ Source text - (http://bit.ly/2yzul1n) Further company coverage:

18 Oct 2017

'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

13 Sep 2017

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

Sept 13 A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

13 Sep 2017

Earnings vs. Estimates